Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 7/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | F10 | P00742 | 5/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | QPCT | Q16769 | 1/20 | 0.33 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.33 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5776711 | 0.85 | BRD4 (0.40) | ROCK2JAK3GRM5BRD4CREBBP | |
| SCHEMBL5779815 | 0.82 | GPR119 (0.46) | ROCK2BRD4CREBBP | |
| SCHEMBL5779808 | 0.82 | GPR119 (0.46) | ROCK2BRD4CREBBP | |
| SCHEMBL5779994 | 0.80 | WNT1 (0.34) | JAK3LMNAPKMIMPDH2IMPDH1 | |
| SCHEMBL5779732 | 0.71 | JAK3 (0.64) | JAK3LMNAIMPDH2MEN1KMT2A | |
| SCHEMBL5779730 | 0.71 | JAK3 (0.64) | JAK3LMNAIMPDH2MEN1KMT2A | |
| SCHEMBL5780655 | 0.69 | JAK3 (0.51) | ROCK2JAK3LMNAPKMQPCT | |
| SCHEMBL5778469 | 0.69 | PTK2 (0.41) | JAK3LMNAPKMIMPDH2IMPDH1 | |
| SCHEMBL5775215 | 0.69 | CD38 (0.43) | JAK3LMNAPKMQPCTIMPDH2 | |
| SCHEMBL5780662 | 0.68 | CDK4 (0.41) | LMNAPKMIMPDH2IMPDH1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276433-A1 | Hydrazone derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-12-07 | — | — | US | disclosed |
| EP-1612204-A1 | HYDRAZONE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276433-A1 | Hydrazone derivative | APP, PRNP, HTT | ROCK2 4262/4885JAK3 4560/4885GRM5 1561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.